文献速递创伤与烧伤重症综合管理与镇静镇痛

创伤与急诊外科中利伐沙班抗凝管理:并发症与逆转策略与华法林治疗的比较

Management of anticoagulation with rivaroxaban in trauma and acute care surgery: Complications and reversal strategies as compared to warfarin therapy.
PubMed 文献 · J Trauma Acute Care Surg · 2017-01-01
一句话结论创伤与急诊外科患者中,利伐沙班与华法林相比出血并发症无显著差异,利伐沙班逆转治疗更少、所需逆转药物更少。

本研究为单中心倾向评分匹配分析,纳入创伤与急诊普通外科(EGS)因房颤或静脉血栓栓塞症(VTE)服用利伐沙班或华法林的患者,将96例利伐沙班组与192例华法林组按1:2匹配。两组出血并发症(37% vs 39%,p=0.49)、VTE并发症(4.2% vs 5.7%,p=0.44)及死亡率(4.2% vs 5.8%,p=0.63)均无显著差异。利伐沙班组住院期间接受外科或介入放射操作的比例更低(32% vs 43%,p=0.01),但针对出血的操作比例无差异(10% vs 12%,p=0.68)。利伐沙班组较少进行抗凝逆转(34% vs 46%,p=0.01)或使用多种逆转药物(20% vs 29%,p=0.02)。回归分析证实抗凝药物类型与出血并发症无关(利伐沙班 vs 华法林相对风险1.02;95%CI 0.85-1.22,p=0.85)。

要点

  • 创伤与EGS患者中,利伐沙班与华法林出血并发症无显著差异(37% vs 39%,p=0.49)。
  • 利伐沙班组住院期间外科或介入放射操作更少(32% vs 43%,p=0.01),但针对出血的操作无差异(10% vs 12%,p=0.68)。
  • 利伐沙班组抗凝逆转更少(34% vs 46%,p=0.01),使用多种逆转药物也更少(20% vs 29%,p=0.02)。
  • 抗凝类型与出血并发症无关(利伐沙班 vs 华法林相对风险1.02;95%CI 0.85-1.22,p=0.85)。
  • 利伐沙班与华法林VTE并发症(4.2% vs 5.7%,p=0.44)及死亡率(4.2% vs 5.8%,p=0.63)无显著差异。

适用人群与场景

  • 单中心四级转诊中心创伤与急诊普通外科(EGS)患者,因房颤或VTE服用利伐沙班或华法林者。
  • 两组在年龄/性别、入院收缩压/心率、入院血红蛋白、损伤严重度评分(创伤患者)及需ICU入住方面匹配良好,无显著差异。

研究设计与关键结果

  • 研究类型:单中心倾向评分匹配分析,192例华法林患者与96例利伐沙班患者按1:2匹配。
  • 主要终点出血并发症:利伐沙班组37% vs 华法林组39%,p=0.49,无显著差异。
  • 次要终点VTE并发症:利伐沙班组4.2% vs 华法林组5.7%,p=0.44,无显著差异。
  • 次要终点死亡率:利伐沙班组4.2% vs 华法林组5.8%,p=0.63,无显著差异。
  • 住院期间外科或介入放射操作:利伐沙班组32% vs 华法林组43%,p=0.01,利伐沙班组更少。
  • 针对出血的操作:利伐沙班组10% vs 华法林组12%,p=0.68,无显著差异。
  • 抗凝逆转:利伐沙班组34% vs 华法林组46%,p=0.01,利伐沙班组更少。
  • 使用多种逆转药物:利伐沙班组20% vs 华法林组29%,p=0.02,利伐沙班组更少。

证据类型、等级与局限

  • 证据类型:治疗性研究,证据等级II级。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,利伐沙班逆转较少见且所需药物较少,而出血并发症和止血干预在这两种抗凝药物之间似乎没有差异。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Rivaroxaban has gained popularity as an anticoagulant (AC) for stroke prevention in nonvalvular atrial fibrillation (afib) and venous thromboembolism (VTE). Although adverse bleeding events are associated with all AC, lack of point-of-care testing to measure the effect of rivaroxaban in emergent situations has contributed to perceived increased risk among physicians.

METHODS: This study aims to describe a single-center experience with trauma and emergency general surgery (EGS) patients taking rivaroxaban and evaluate outcomes compared with patients taking warfarin using a propensity score analysis. Trauma and EGS patients taking rivaroxaban or warfarin for afib/VTE over a 2-year period were eligible for inclusion and matched for injury/illness severity in a 1:2 ratio using propensity score matching. In a single quaternary referral center, 192 warfarin patients were matched to 96 rivaroxaban patients. Groups were well matched with no significant difference in age/sex, admission systolic blood pressure/heart rate, admission hemoglobin, injury severity score (trauma patients), or need for ICU admission. Conditional logistic regression determined association of AC type with bleeding complications, adjusting for age/sex, AC indication, coagulation laboratory values, antiplatelet medications or other AC, comorbidities, renal impairment, and operative intervention. Primary outcome was bleeding complications, defined as hemorrhage during admission or as a presenting problem. Secondary outcomes included invasive interventions, AC reversal, VTE complications, and mortality.

RESULTS: There was no difference between rivaroxaban and warfarin for bleeding complications (37% vs. 39%, p = 0.49), VTE complications (4.2% vs. 5.7%, p = 0.44), or mortality (4.2% vs. 5.8%, p = 0.63). Fewer rivaroxaban patients underwent surgical or interventional radiology procedures during admission (32% vs. 43%, p = 0.01), but there was no difference in procedures specifically for bleeding (10% vs. 12% p = 0.68). Rivaroxaban patients less frequently underwent AC reversal (34% vs. 46%, p = 0.01) or received multiple reversal agents (20% vs. 29%, p = 0.02). Regression analysis confirmed AC type was not associated with bleeding complications (rivaroxaban vs. warfarin relative risk 1.02; 95% CI 0.85-1.22, p = 0.85).

CONCLUSION: Reversal of rivaroxaban was less common and required fewer agents, whereas bleeding complications and hemostatic interventions do not seem to be different between these AC types.

LEVEL OF EVIDENCE: Therapeutic study, level II.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Myers SP, Dadashzadeh ER, Cheung J, et al. Management of anticoagulation with rivaroxaban in trauma and acute care surgery: Complications and reversal strategies as compared to warfarin therapy. J Trauma Acute Care Surg. 2017. PMID: 28045742. doi:10.1097/TA.0000000000001340

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。